Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel

JAMA

Volumn 283, Issue 3, 2000, Pages 381-390

  Carpenter, Charles C J ^a   Cooper, David A ^b   Fischl, Margaret A ^c   Gatell, Jose M ^d   Gazzard, Brian G ^e   Hammer, Scott M ^f   Hirsch, Martin S ^g   Jacobsen, Donna M ^h   Katzenstein, David A ⁱ   Montaner, Julio S G ^j   Richman, Douglas D ^k   Saag, Michael S ^l   Schechter, Mauro ^m   Schooley, Robert T ⁿ   Thompson, Melanie A ^o   Vella, Stefano ^p   Yeni, Patrick G ^q   Volberding, Paul A ^r  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h International AIDS Society USA   (United States)

ⁱ STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^j ST PAUL S HOSPITAL   (Canada)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

ⁿ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^o AIDS Research Consortium of Atlanta   (United States)

^p ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^q BICHAT HOSPITAL   (France)

^r UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG APPROVAL; DRUG FORMULATION; DRUG INDUCED DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT FAILURE; TREATMENT INDICATION; VIRUS INFECTION;

EID: 0034685037     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.3.381     Document Type: Review

References (113)

1. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. JAMA. 1996;276:146-154.
2. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA. 1997;277:1962-1969.
3. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. JAMA. 1998;280:78-86.
4. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in HIV-1 infection. Nature. 1995;373:117-122.
5. +lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
6. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med. 1996;2:625-629.
7. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996;348:283-291.
8. + cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081-1090.
9. Hammer SM, Squires KE, Hughes MD, et al. Controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200/mL or less. N Engl J Med. 1997;337:725-733.
10. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997; 337:734-739.
11. Perelson AS, Essunger P, Cao Y. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature. 1997;387:188-191.
12. US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. MMWR Morb Mortal Wkly Rep. 1998;47(RR-5):42-82.
13. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo. Science. 1996;271:1582-1586.
14. Zhang L, Ramratriam B, Tenner Racz K. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999; 340:1605-1613
15. 15; Hockett RD, Kilby JM, Derdeyn CA, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med. 1999;189:1545-1559.
16. Gunthard HF, Frost SD, Leigh-Brown AJ, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol. 1999;73:9404-9412.
17. +T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517.
18. Fauci AS. Multifactoriaf nature of human immunodeficiency virus disease. Science. 1993;262:1011-1018.
19. + T cell responses associated with control of viremia. Science. 1997;278:1447-1450.
20. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998;4:553-956.
21. Autran B, Carcelain G, Tubiana R. et al. Effects of antiretroviral therapy on immune reconstitution. From: 6th Conference on Retroviruses and Opportunistic infections; January 31-February 4, 1999; Chicago, Ill. Abstract S44.
22. Bucy RP, Rockett RD, Derdeyn CA, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest. 1999;103:1391-1398.
23. Plana M, Garcia P, Gallart I, et al. Lack of T-cell proliferative response to HIV-1 antigens after one year of highly active antiretroviral therapy in early HIV-1 disease. Lancet 1998;352:1194-1195
24. Dong KL, BaUsserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr. 1999;21:107-113.
25. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidemia and diabetes mellitus. Lancet 1999;353:2093-2099.
26. Henry K. Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors (letter). Lancet. 1998;351:1328.
27. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
28. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet. 1997;349:1294.
29. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-454.
30. Schechter M, Struchiner CJ, Harrison LH. Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression. AIDS. 1999; 13:97-102,
31. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
32. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177:40-47.
33. Lyles R, Munoz A, Bazmi H, et al. Natural history of HIV-1 viremia after seroconversion in the Multicenter AIDS Cohort Study. From: 6th Conference on Retroviruses and Opportunistic infections; January 31-February 4, 1999; Chicago, Ill. Abstract 273.
34. Farzadegan H, Hoover DR, Astemborskl J. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 1998;352:1510-1514.
35. Anastos K, Gange SJ, Lau B, et al. Gender-specific differences in quantitative HIV-1 RNA levels. From: 6th Conference on Retroviruses and Opportunistic Infections, January 31-February 4. 1999; Chicago, Ill. Abstract 274.
36. Sterling TR, Lyles CM, Vlahov D, et al. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis. 1999; 180:666-672.
37. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):1-19.
38. Markowitz M, Jin X, Ramratnam B, et al. Virologic and immunologic profiles of newly Infected individuals electing discontinuation of HAART after approximately three years of apparently suppressive therapy, from: 39th Interscienee Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract LB-16.
39. Hsu A, Granneman GR, Cao G, et al. Pharmaco-kinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother. 1998;42:2784-2791.
40. Saah AJ, Winchell G, Seniuk M, Deutsch P. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) ritonavir (RTV) combinations in healthy volunteers. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 362
41. Burger DM, Hugen PWH, Prins JM, et al. Pharmacokinetics of an Indinavir/Ritonavir 800/100 mg BID regimen. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 363.
42. McCrea J, Buss N, Stone J, et al. indinavir-saquinavir single dose pharmacokinetic study. From: 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 608.
43. Buss N, and the Fortovase Study Group, Saquinavir soft gei capsule (Fortovase). From: 5th Conference on Retroviruses and Opportunistic infections; February 1-5, 1998; Chicago, Ill. Abstract 354.
44. Yuen G, Kerr, B, Lee C, et al. Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate (NFV), a new HIV-1 protease inhibitor. From: 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 373.
45. Squires K, Riddler S, Haviir D, et al. Co-administration of indinavir (IDV) 1200 mg with neffinavir (NFV) 1250 mg in a twice daily regimen. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 364.
46. Sadler B, Gillotin C, Chittlick GE, et .al. Pharmacokinetic drug interactions with amprenavir. From: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12389.
47. Murphy R. Gagnier P. Lamson M, et al. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-1 patients; From: 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 374.
48. Ferry JJ, Herman BD, Cox SR, et al. Delavirdine and indinavir. From: 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 392.
49. Ferry JJ, Schneck DW, Carlson GF, et al. Evaluation of the pharmacokinetic interaction between ritonavir and delavirdine in healthy volunteers. From: 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 372.
50. Fiske WD, Mayers D, Wagner KF. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals. From: 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 568.
51. Flexner C, Hsu A, Kerr B. Steady-state pharmacokinetic interactions between ritonavir, neffinavir, and the nelfinavir active metabolite M8 (AG 1402). From 12th World AIDS Conference; June 23-July July 3, 1998; Geneva, Switzerland. Abstract 42265.
52. Gallant JE, Raines C, Sun E, et al. A Phase II study of ritonavir-nelfinavir combination therapy. From: 6th Conference on Retroviruses and Opportunistic infections; January 31-February 4, 1999; Chicago, Ill. Abstract 393.
53. Shefton M, Hewitt RG, Adams JM, et al. Delvirdine mesylate pharmacokinetics during combination therapy with ritonavir. from: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abtract A-63.
54. Efavirenz [package insert]. Wilmington, Del: DuPont Pharmaceuticals Co; 1998.
55. Slater L, Sension M, Feinberg J, et al. Fortovase BID regimens in HIV-1 infected patients. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-Febryary 4, 1999; Chicago, Ill. Abstract 390.
56. Sahai J, Cameron W, Salgo M, et al. Drug interaction study between saquinavir and nevirapine. From: 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 614.
57. Kravcik S, Sahai H, Kerr B, et al. Nelfinavir mesylate increases saquinavir soft-gei capsule exposure in HIV-positive patients. From: 4th Conference on Retroviruses and Opportunistic infections: January 22-26, 1997; Washington. DC. Abstract 371.
58. Skowron G, Leoung G, Kerr B, et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS. 1998;12:1243-1244.
59. Cox SR, Schriek DW, Herman BD, et al. Delavirdine (DLV) and nelfinavir (NFV). From: 5th Conference on Retroviruses and Opportunistic infections; February 1-5, 1998; Chicago, Ill. Abstract 345.
60. Wathen L, Slater L, Kuritzkes D, et al. Significant decreases in viral burden with twice daily dosing of delavirdine in combinations with neifinavir, didanosine, and stavudine. Antiviral Ther. 1998;3(suppl 5):95-96.
61. Fiske WD, Benedek EH, White SJ, et al. Pharmacokinetic interaction between DMP266 and nelfinavir mesylate in healthy volunteers. From: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-Octeber 1, 1997; Toronto, Ontario. Abstract 1-174.
62. Fiske WD, Benedek LH, White SJ, et al. Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers, from: 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 349.
63. Eron J, Walmsley S, Wathen L, et al. Sustained viral suppression with delavirdine and indinavir combination therapies. From: 6th Conference on Retroviruses and Opportunistic infections; January 31-February 4, 1999; Chicago, Ill. Abstract 384.
64. Acosta EP, Gulick R, Katzenstein D, et al. Pharmacokinetic (PK) evaluation of saquinavir soft gel capsules (SQV)/ritonavir (RTV) or SQV/nelfinavir (NFV) in combination with delavirdine (DLV) and/or adefovir dipivoxil (ADV) - ACTC 359. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 365.
65. Staszewski S, Keiser P, Gathe J, et al. Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapy-naïve adults at 48 weeks. From: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 505.
66. Murphy RL, Katlama C, Johnson V, et al. The Atlantic study. From: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract LB-22.
67. Hirsch MS, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis. 1999;180:659-665.
68. Fischl M, Greenberg S, Clumeck N, et al. Ziagen (Abacavir, ABC, 1592) combined with 3TC & ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naive subjects (CNAA3003). From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 19.
69. Staszewski S, Morales-Ramirez J, Tashima TK, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
70. Manion DJ, Labriola DF, Ruiz NM. Efficacy of efavirenz (SUSTIVA) containing regimens in patients with baseline plasma HIV-RNA viral loads exceeding 100,000 copies/ml. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 383.
71. Montaner JSG, Reiss P, Cooper D, et al. Randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA. 1998;279:930-937.
72. Katlama C, Murphy R, Johnson V, et al. The Atlantic study. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 18.
73. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine. Antimicrob Agents Chemother. 1993;37:178-182.
74. Sargent S, Green S, Para M, et al. Sustained plasma viral burden reductions and CD4 increases in HIV-1 infected patients with RESCRIPTOR (DLV) + RETROVIR (ZDV) + EPIVIR (3TC). From: 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 699.
75. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA. 1998;280:35-41.
76. Saag M, Krowles M, Chang Y, et al. Durable effect of VIRACEPT (nelfinavir mesylate, NFV) in triple combination therapy. From: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract 1-101.
77. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease Lancet. 1998;315:543-549.
78. Murphy RL, De Gruttola V, Gulick RM, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis. 1999;179:808-816.
79. Paterson D, Swindells S, Mohr J, et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 92.
80. Hecht FM. Measuring HIV treatment adherence in clinical practice. AIDS Clin Care. 1998;10:57-59.
81. Brambilla D, Reichelderfer PS, Bremer JW, et. al. The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. AIDS. 1999;13:2269-2279.
82. Kempf D, Rode R, Xu Y, et al. Duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9-F14.
83. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998;12:1619-1624.
84. Demeter L, Hughes M, Fischl M, et al. Predictors of virologic and clinical responses to indinavir (IDV) + ZDV + 3TC or ZDV + 3TC. From: 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 509.
85. Garraffo R, Durant J, Clevenbergh P. Relevance of protease inhibitor plasma levels in patients treated with genotypic adapted therapy [abstract]. Antiviral Therapy. 1999;4(suppl 1):75.
86. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in HIV infection of adults. JAMA. 1998;279:1984-1991.
87. Clevenbergh P, Durant J, Halfen P, et al. Persisting long-term benefit of antiretroviral genotypic guided treatment for HIV-infected patients failing HAART. Antiviral Ther. 1999;4(suppl 1):42.
88. Baxter JD, Mayers DL, Wentworth DN, et al. Final results of CPCRA 046. [abstract]. Antiviral Ther. 1999;4(suppl 1):43.
89. Call S, Westfall A, Cloud C, et al. Predictive value of HIV phenotypic susceptibility testing in a clinical cohort. From: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract LB-17.
90. Schuurman R, Demeter L, Reichelderfer P, et al. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol. 1999;37:2291-2296.
91. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients. Lancet. 1999;353:863-868.
92. Deeks S, Barbour J, Swanson M, et al. Sustained CD4 T cell response after virologic failure of protease inhibitor based regimens. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 494.
93. + cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet. 1998;351:723-724.
94. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283:229-234.
95. Holder DJ, Condra JH, Schleif WA, et al. Virologic failure during combination therapy with CRIXIVAN and RT inhibitors is often associated with expression of resistance-associated mutations in RT only. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 492.
96. Descamps D, Peytavin G, Calvez V, et al. Virologic failure, resistance and plasma drug measurements in induction maintenance therapy trial (ANRS 072, Trilège). From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 493.
97. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic. AIDS. 1999;13:F35-F43.
98. Phillips P, Kwiatkowski MB, Copland M, et al. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol. 20;1999:122-128.
99. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet. 1997;350:1596.
100. Lo JC, Mulligan K, Tai VW, et al. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998;351:867-870.
101. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy AIDS. 1997;11:938-939.
102. Ruiz L, Bonjoch A, Paredes R, et al. A multicenter, randomized, open-label, comparative trial of the clinical benefit of switching the protease inhibitor (PI) by nevirapine (NVP) in HAART-experienced patients suffering lipodystrophy (LD). From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract LB14.
103. Neumann AU, Tubiana R, Calvez V. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS. 1999;13:677-683.
104. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who have previously failed nelfinavir. AIDS. 1999;13:F23-F28.
105. Ait-Khaled M, Stone C, Mesogiti D, et al. Geno-type and phenotype of HIV-1 in ART experienced adults prior and following therapy with Ziagen (Abacavir, ABC) added to stable background therapy (ABC + SBG). From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 114.
106. Miller MD, Anton KE, Mulato AS, et al. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis. 1999;179:92-100.
107. Race E, Ferchal F, Dam E, et al. Selection of HIV-1 variants with wide cross-resistance to reverse transcriptase inhibitors during low-level escape to first-line dual nucleoside therapy [abstract] Antiviral Ther. 1999;4(suppl 1):80.
108. Ross L, Danehower S, Johnson M, et al. Stavudine-based combination and monotherapy selects for zidovudine resistance HIV-1 mutations in zidovudine-naive adults and in paediatric patients. Antiviral Ther. 1999;4(suppl 1):79.
109. Coakley E, Gillis J, Hammer S. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine in combination. AIDS. In press.
110. Miller V, Gute P, Carlebach A, et al. Baseline resistance and virological response to mega-HAART salvage therapies. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 130.
111. Montaner JS, Harrigan R, Jahnke N, et al. Multi-drug rescue therapy (MDRT) for HIV-infected individuals with prior virologic failure to multiple regimens [abstract]. Antiviral Ther. 1998;3(suppl 5):80.
112. Miller V, Rottman C, Hertogs K. Mega-HAART, resistance and drug holidays. Antiviral Ther. In press.
113. Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health-care worker exposure to HIV and recommendations for postexposure prophylaxis. MMWK Morb Mortal Wkly Rep. 1998;47(RR-7):1-33.